298 related articles for article (PubMed ID: 11745445)
1. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.
Blumenthal RD; Taylor A; Osorio L; Ochakovskaya R; Raleigh JA; Papadopoulou M; Bloomer WD; Goldenberg DM
Int J Cancer; 2001 Nov; 94(4):564-71. PubMed ID: 11745445
[TBL] [Abstract][Full Text] [Related]
2. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts.
Blumenthal RD; Sharkey RM; Natale AM; Kashi R; Wong G; Goldenberg DM
Cancer Res; 1994 Jan; 54(1):142-51. PubMed ID: 8261435
[TBL] [Abstract][Full Text] [Related]
3. The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts.
Wilder RB; McGann JK; Sutherland WR; Waller EK; Minchinton AI; Goris ML; Knox SJ
Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):119-26. PubMed ID: 8270432
[TBL] [Abstract][Full Text] [Related]
4. Colonic tumor CEA, CSAp and MUC-1 expression following radioimmunotherapy or chemotherapy.
Modrak DE; Gold DV; Goldenberg DM; Blumenthal RD
Tumour Biol; 2003; 24(1):32-9. PubMed ID: 12743424
[TBL] [Abstract][Full Text] [Related]
5. Changes in tumor vascular permeability in response to experimental radioimmunotherapy: a comparative study of 11 xenografts.
Blumenthal RD; Sharkey RM; Kashi R; Sides K; Stein R; Goldenberg DM
Tumour Biol; 1997; 18(6):367-77. PubMed ID: 9372870
[TBL] [Abstract][Full Text] [Related]
6. Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer.
Stein R; Juweid M; Zhang CH; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3199s-3206s. PubMed ID: 10541364
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
Papadopoulou MV; Ji M; Ji X; Bloomer WD; Hollingshead MG
Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478
[TBL] [Abstract][Full Text] [Related]
8. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine.
Beck R; Röper B; Carlsen JM; Huisman MC; Lebschi JA; Andratschke N; Picchio M; Souvatzoglou M; Machulla HJ; Piert M
J Nucl Med; 2007 Jun; 48(6):973-80. PubMed ID: 17536108
[TBL] [Abstract][Full Text] [Related]
10. Myelosuppressive changes from single or repeated doses of radioantibody therapy: effect of bone marrow transplantation, cytokines, and hematopoietic suppression.
Blumenthal RD; Alisauskas R; Lew W; Sharkey RM; Goldenberg DM
Exp Hematol; 1998 Aug; 26(9):859-68. PubMed ID: 9694507
[TBL] [Abstract][Full Text] [Related]
11. Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine.
Stein R; Chen S; Reed L; Richel H; Goldenberg DM
Cancer; 2002 Jan; 94(1):51-61. PubMed ID: 11815960
[TBL] [Abstract][Full Text] [Related]
12. The combined use of 131I-labeled antibody and the hypoxic cytotoxin SR 4233 in vitro and in vivo.
Langmuir VK; Mendonca HL
Radiat Res; 1992 Dec; 132(3):351-8. PubMed ID: 1475358
[TBL] [Abstract][Full Text] [Related]
13. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 2001; 12(8):325-33. PubMed ID: 11589303
[TBL] [Abstract][Full Text] [Related]
14. The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.
Lunt SJ; Cawthorne C; Ali M; Telfer BA; Babur M; Smigova A; Julyan PJ; Price PM; Stratford IJ; Bloomer WD; Papadopoulou MV; Williams KJ
Br J Cancer; 2010 Jul; 103(2):201-8. PubMed ID: 20588272
[TBL] [Abstract][Full Text] [Related]
15. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts.
Wilder RB; Langmuir VK; Mendonca HL; Goris ML; Knox SJ
Cancer Res; 1993 Jul; 53(13):3022-7. PubMed ID: 8319209
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-dependent retinal toxicity of NLCQ-1 (NSC 709257) in BALB/c mice. Comparison with tirapazamine.
Papadopoulou MV; Ji M; Bloomer WD
Basic Clin Pharmacol Toxicol; 2011 Jun; 108(6):396-9. PubMed ID: 21205223
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, toxicity and mode of interaction of combination radioimmunotherapy with 5-fluorouracil in colon cancer xenografts.
Kinuya S; Yokoyama K; Tega H; Hiramatsu T; Konishi S; Watanabe N; Shuke N; Aburano T; Takayama T; Michigishi T; Tonami N
J Cancer Res Clin Oncol; 1999 Nov; 125(11):630-6. PubMed ID: 10541970
[TBL] [Abstract][Full Text] [Related]
18. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 2000; 12(4):185-92. PubMed ID: 11341468
[TBL] [Abstract][Full Text] [Related]
19. The effect of low pH and hypoxia on the cytotoxic effects of SR4233 and mitomycin C in vitro.
Skarsgard LD; Vinczan A; Skwarchuk MW; Chaplin DJ
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):363-7. PubMed ID: 8195034
[TBL] [Abstract][Full Text] [Related]
20. NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts.
Papadopoulou MV; Bloomer WD; Hollingshead MG
Anticancer Res; 2005; 25(3B):1865-9. PubMed ID: 16158918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
